Skip to main content

Table 3 Ongoing clinical trials of ASP8273

From: Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer

Phase Study population NCT no.
Phase I NSCLC patients who have EGFR mutations and received prior treatment with EGFR TKI 02113813
Phase I/II NSCLC with EGFR mutation and had progressive disease after previous treatment with EGFR TKIs 02192697
Phase II NSCLC with EGFR mutation and TKI naïve patients 02500927
Phase III Stage IIIB/IV NSCLC with EGFR mutations 02588261
  1. EGFR: epidermal growth factor receptor, NSCLC: non-small cell lung cancer, TKI: tyrosine kinase inhibitor